Androgen receptor (AR) recruitment of transcriptional corepressors NCoR and SMRT can be enhanced by antagonists such as mifepristone. This study shows that enhanced NCoR binding to the mifepristone-liganded AR is mediated by the NCoR COOH-terminal N1 CoRNR box and that this selectivity is due to charged residues unique to the COOH-terminal CoRNR boxes of NCoR and SMRT. Significantly, these residues are on a helical face adjacent to oppositely charged residues in helix 4 of the AR ligandbinding domain. Mutagenesis of these AR residues in helix 4, as well as mutation of lysine 720 in helix 3 (predicted to interact with the CoRNR box), markedly impaired AR recruitment of NCoR, indicating that N1 CoRNR box binding is being stabilized by these ionic interactions in the AR ligand-binding domain coactivator/corepressor binding site. Finally, results using a helix 12 -deleted AR indicate that mifepristone induces allosteric changes in addition to helix 12 displacement that are critical for NCoR binding. These findings show that AR antagonists can enhance corepressor recruitment by stabilizing a distinct antagonist conformation of the AR coactivator/corepressor binding site and support the development of additional antagonists that may be able to further enhance AR recruitment of corepressors.
Introduction
The androgen receptor (AR) is a member of the steroid receptor/nuclear receptor family that plays a major role in normal prostate growth and in the development and progression of prostate cancer. Similarly to other nuclear receptors, binding of agonist ligands causes a shift in the position of helix 12 in the AR ligand-binding domain (LBD) toward helices 3 to 5, which both stabilizes ligand binding and generates a hydrophobic cleft for binding of coactivator proteins via leucine-X-X-leucine-leucine (LXXLL) motifs (1, 2) . A unique feature of AR is that an LXXLL-like motif in the NH 2 terminus (amino acids 23-27, FQNLF) binds to this hydrophobic cleft, which further stabilizes helix 12 and ligand binding (3 -10) . In the absence of ligand, nonsteroidal nuclear receptors such as thyroid and retinoid receptors repress transcription by recruiting the corepressor proteins NCoR and SMRT, which are associated with histone deacetylases (11 -15) . Corepressor binding is mediated by extended LXXLL-like motifs (L-X-X-I/H-I-X-X-X-L/I), termed corepressor nuclear receptor boxes (CoRNR boxes), which are located in the COOH-terminal half of NCoR and SMRT (16 -23) . The positioning of helix 12 away from helices 3-5 in unliganded (or antagonist liganded) nuclear receptors opens the LXXLL site to accommodate these larger CoRNR boxes, with three helical turns (versus two turns for LXXLL motifs; ref. 24) .
Although the nonsteroidal nuclear receptors bind DNA in the absence of ligand and actively repress transcription via NCoR and SMRT recruitment, DNA binding by steroid receptors is generally ligand dependent and mediated physiologically by agonist ligands. Nonetheless, certain steroid hormone receptor antagonists (or partial agonists) can stimulate DNA binding and recruitment of NCoR or SMRT. This seems to be the mechanism of action for the estrogen receptor a (ERa) antagonists tamoxifen and raloxifene. Crystal structures of the tamoxifen-and raloxifene-liganded ERa show that the side groups of these drugs force alternative nonagonist positions for helix 12 (25, 26) . This repositioning of helix 12 allows for corepressor binding, and the tissue-selective activities of these drugs (antagonists in breast cancer and agonists in bone and other tissues) seem to reflect the relative levels of transcriptional coactivators versus corepressors in the respective tissues (27) . Biochemical studies of mifepristone (RU486), an antagonist of the glucocorticoid receptor and progesterone receptor (PR), indicate that antagonist activity is similarly due to recruitment of NCoR or SMRT (28 -30) . The critical structural feature of mifepristone is a bulky phenyl-aminodimethyl group in the 11h position that is presumed to displace helix 12. Therefore, although the physiologic roles of NCoR and SMRT in the normal functioning of ERa, PR, and glucocorticoid receptor are uncertain, drugs that stimulate recruitment of these corepressors can be developed and have important clinical activities.
In contrast to other steroid receptors, the agonistliganded AR interacts with NCoR and SMRT (31 -33) , and RNA interference approaches have shown that NCoR and SMRT function at physiologic levels as negative regulators of androgen (testosterone and dihydrotestosterone, DHT) -stimulated AR transcriptional activity (34) (35) (36) . Moreover, AR recruitment of NCoR, as assessed by chromatin immunoprecipitation, is increased by AR antagonists or partial agonists (bicalutamide, cyproterone acetate, or mifepristone), and NCoR/SMRT down-regulation can increase the agonist activity of drugs such as hydroxyflutamide that have partial agonist activity (34, 35, 37 -40) . Significantly, the interactions between AR and these corepressors is complex, as NCoR and SMRT seem to interact with both the AR NH 2 -terminal and LBDs (32, 34, 41, 42) .
We have screened candidate compounds for drugs that can enhance the AR-NCoR interaction and may therefore function as novel and more potent AR antagonists. Mammalian one-and two-hybrid protein interaction studies indicate that physiologic weak androgens and AR antagonists currently used in prostate cancer patients do not substantially increase AR binding of NCoR (34) . In contrast, mifepristone, a progesterone and glucocorticoid receptor antagonist with weak partial agonist activity on the AR (43), can strongly enhance AR-NCoR and AR-SMRT binding (34, 39, 44) . Previous results indicate that the interaction between NCoR and the mifepristone-liganded AR is dependent on a region encompassing the COOHterminal CoRNR box (N1) and that both the AR NH 2 -terminal and LBDs are required to mediate the interaction (34) . One interpretation of these data is that mifepristone alters the structure of the LXXLL coactivator-binding site in the AR LBD to allow for CoRNR box binding. However, there are no available data on antagonist conformations of AR, and the molecular basis for AR interaction with corepressor proteins remains unclear. Therefore, the objectives of this study were to determine the basis for NCoR binding to the mifepristone-liganded AR and to develop a model that can be used for the development of further more active AR antagonists.
Materials and Methods

Plasmids and Reagents
Expression vectors for AR (pSVARo), VP16-AR, VP16-TRh1, VP16-NCoR fusions, Gal4-NCoR fusions, full-length NCoR (PKCR2-NCoR), and Gal4-RARa have been described previously (22, 31, 34, 45) . All amino acid residue numbering for NCoR is based on the human NCoR sequence. Mutant pSVARo, NCoR, Gal4-NCoR, and VP16-NCoR constructs were created by site-directed mutagenesis using the Quick-Change Site Directed Mutagenesis kit (Stratagene). The AR constructs with NH 2 -terminal deletions (del 1-11 and del 1-37) and the control for these mutants (KNHA-AR) have an NH 2 -terminal HA-tag and were kindly provided by Dr. Michael Lu (Department of Biomedical Sciences, Florida Atlantic University, Boca Raton, FL; ref. 46 ). The helix 12 -deleted AR was derived from pSVARo by inserting a stop codon in place of methionine at residue 886. The reporter construct ARE 4 -luciferase, containing four tandem copies of a synthetic ARE, has been described (31) . pG5-luciferase, regulated by five tandem Gal4 binding sites, and pRL-CMV, a CMV promoter regulated Renilla control, were from Promega. DHT and mifepristone were from Sigma and were used as 1:1,000 stock solutions in ethanol.
Cell Culture and Transfection CV1 and COS7 cells were maintained in DMEM supplemented with 10% fetal bovine serum (Hyclone). Cells in 48-well tissue culture plates in DMEM containing 10% charcoal dextran-stripped fetal bovine serum (Hyclone) were cotransfected using Lipofectamine 2000 (Invitrogen). Cells were transfected with 100 ng of reporter and expression vectors, except where indicated per well, and 1.25 ng of pRL-CMV Renilla vector for normalization. After 24 h, the medium was replaced with fresh DMEM containing 10% charcoal dextran-stripped fetal bovine serum with hormones or drugs at the indicated final concentrations. Following a further 24 h, firefly and Renilla luciferase activities were assayed with the dual-luciferase assay system as per the supplier's instructions (Promega). All samples were in triplicate and firefly luciferase activities were normalized for cotransfected Renilla activity.
Results
NCoR Interaction with the AR NH 2 -Terminal Domain Is Mediated by a Region Flanking the N2 CoRNR Box
Previous studies have shown that mifepristone can enhance AR binding to NCoR and that both the AR NTD and the LBD are required for this mifepristone-enhanced NCoR-AR interaction (34) . We have further shown that this NCoR interaction with the mifepristone-liganded AR is mediated by a COOH-terminal fragment of NCoR containing the N2 and N1 CoRNR boxes (see diagram in We previously showed that removal of a region encompassing the N1 CoRNR box abrogated NCoR binding to the mifepristone-liganded AR (34) . To further assess whether the N1 CoRNR box mediates the interaction with the mifepristone-liganded AR LBD, we mutated a double isoleucine in N1 to alanines in the NCoR(1806-2440) fragment, which contains all three CoRNR boxes. We also mutated a double isoleucine in the N2 CoRNR box to alanines. These fragments were fused to the Gal4 DBD and assessed for interaction with VP16-AR using a pG5-luciferase reporter. There was a strong interaction between the mifepristone-liganded VP16-AR and Gal4DBD-NCoR(1806-2440) and this interaction was not impaired by the N2(AA) mutation ( Fig. 2A) . However, the interaction was abrogated by the N1(AA) mutation, indicating that the N1 CoRNR box was critical for binding. As a further control to confirm that the N1(AA) mutation was not nonspecifically altering the structure or expression of the protein, we determined whether the interaction with unliganded TRh (which is mediated by the N3 CoRNR box) was intact. As shown in Fig. 2B , the wild-type, N1(AA) and N2(AA) Gal4-NCoRc interacted with the VP16-TRh.
To confirm that the N1 CoRNR box was critical for binding to the intact AR bound to an androgen-responsive element, we cloned the N1(AA) mutation into the VP16-NCoR(1806-2440) vector. As shown in Fig. 3C , the N1(AA) mutation abrogated NCoR recruitment by the mifepristoneliganded wild-type AR. The N1(AA) mutation cloned into the VP16-NCoR(2005-2440) vector (containing the N2 and N1 CoRNR boxes) similarly abrogated recruitment (Fig. 4D) . To control for nonspecific effects of the mutation in the NCoR(2005-2440) fragment, we showed that the mutation did not impair recruitment by the unliganded RARa fused to the Gal4 DNA binding domain (data not shown). Finally, we cloned the N1(AA) mutation into the intact full-length NCoR. As expected, both the wild-type and mutant NCoR could suppress the constitutive activity of the AR NTD (Fig. 3A) . We then assessed inhibition of the DHT versus mifepristone-liganded AR. As the latter does not have substantial transcriptional activity, we carried out these cotransfections with a VP16-AR fusion protein.
Significantly, both the wild-type and N1(AA) mutant NCoR suppressed the DHT-liganded VP16-AR, with the N1(AA) mutant being more effective (Fig. 3B) . The N1AA was also more effective at repressing VP16-AR transactivation by a partial agonist (cyproterone acetate), whereas its effect on a pure antagonist (bicalutamide) was comparable with the wild-type NCoR. In contrast, the N1(AA) mutant was less active at repressing the mifepristone-liganded VP16-AR, consistent with the N1 CoRNR box enhancing recruitment of the full-length NCoR. It should be noted that although the N1(AA) mutation abrogates AR interaction with NCoR COOHterminal fragments, it does not do so in the context of full-length NCoR. This likely reflects additional contacts between NCoR and the AR NTD mediated by the NH 2 -terminal regions of NCoR (42) .
Charged Residues Common to N1 CoRNR Boxes in NCoR and SMRT Are Critical for Binding
A previous study found that the interaction between unliganded AR and SMRT was dependent on the COOHterminal (N1) CoRNR box (33) . An alignment of the SMRT and NCoR CoRNR boxes shows that the N1 CoRNR boxes are almost identical (Fig. 4A) . Moreover, they are distinct from the other CoRNR boxes in having a charged residue (arginine) at position 6. They also share a glutamate at position 2, which is aspartate in the N3 CoRNR box of NCoR and alanine in the other CoRNR boxes. Therefore, we carried out further mutagenesis to determine whether these charged residues common to the NCoR and SMRT COOH-terminal CoRNR boxes contribute to NCoR binding to the mifepristone-liganded AR. Significantly, mutations at either site markedly impaired NCoR recruitment by the mifepristone-liganded AR (Fig. 4B ).
N1Is Interacting with the AR Coactivator Binding Site
To further assess the molecular basis for N1 CoRNR box binding to the AR, and in particular to test the hypothesis that the N1 CoRNR box was binding to the LXXLL coactivator site, we compared the available crystal structures of the agonist-liganded AR binding to a FQNLF peptide and the antagonist-liganded PPARg binding to a SMRT N1 CoRNR box peptide (24) . A conserved lysine at the COOH-terminal end of helix 3 in AR and PPARg anchors both peptides by forming hydrogen bonds with the COOH-terminal phenylalanine or leucine residues, respectively (Fig. 5A) . The FQNLF peptide forms two helical turns and is anchored at its NH 2 terminus by helix 12 in the AR. In contrast, the displacement of this helix in the antagonist conformation of PPARg allows the site to accommodate a third helical turn in the CoRNR box, with leucines at position 1 and 9 and isoleucine at position 5, forming a hydrophobic face that binds to helix 3. Another face of the CoRNR box helix is formed by glutamic acid at position 2 and arginine at position 5, which interact with K310 and N303 in helix 4 of PPARg. Significantly, these residues in PPARg correspond to Q738 and D731 in helix 4 of the AR, suggesting that strong interactions between these acidic and basic residues may stabilize CoRNR box binding to the mifepristone-liganded AR (Fig. 5A) . A recent crystal structure has been reported for the PR complexed with a mifepristone-related antagonist (asoprisnil) and an NCoR N1 CoRNR box (47) . Significantly, this structure shows a similar positioning of the CoRNR box peptide and a bond between glutamic acid at position 2 and a glutamine in PR that is equivalent to Q738 in AR (Fig. 5B) .
To determine whether K720, D731, and Q738 in AR contribute to NCoR binding by the mifepristone-liganded AR, we next examined site-directed mutants. A K720A mutation in the AR only moderately decreased DHTstimulated activity, possibly due to strong hydrophobic interactions mediated by the phenylalanines in the FQNLF peptide (Fig. 5C ). In contrast, the K720A mutation markedly impaired recruitment of VP16-NCoR(2005-2440) in response to mifepristone. The mutations in helix 4 (D731A and Q738A) had substantial effects on DHTstimulated AR activity, but again more markedly impaired the response to mifepristone (Fig. 5D) . Taken together, the NCoR mutagenesis data above and these AR mutagenesis data strongly support the conclusion that the N1 CoRNR box is binding to the coactivator/corepressor binding site in the AR LBD.
Displacement of Helix 12 Is Not Sufficient to Obtain NCoR Recruitment
A structural feature of mifepristone that contributes to its antagonist activity is its bulky phenyl-aminodimethyl group in the 11h position, which is presumed to displace helix 12. However, it was not clear whether helix 12 displacement was sufficient for NCoR binding or whether NCoR binding is enhanced by further ligand-induced allosteric changes in the AR LBD. Therefore, to determine whether mifepristone enhances NCoR recruitment by mechanisms in addition to displacement of helix 12, we generated a mutant AR that was truncated after helix 11. As expected, this mutation markedly impaired transactivation in response to DHT and mifepristone was similarly inactive (Fig. 6A) . Significantly, the truncated AR was not coactivated by VP16-NCoR(2005-2440) in the absence of ligand or in response to DHT, demonstrating that removal of helix 12 alone is not sufficient. In contrast, the truncated mifepristone-liganded AR was strongly coactivated by VP16-NCoR(2005-2440), indicating that NCoR binding was dependent on further ligand-induced conformational changes in the AR LBD. 
Discussion
Structural studies of glucocorticoid receptor, ER, and PR have shown that binding of certain antagonists causes displacement of helix 12, and this seems to allow for CoRNR box -mediated recruitment of NCoR and SMRT. Recent studies have shown that NCoR and SMRT interact with both the agonist and antagonist-liganded AR and that this interaction can be enhanced by certain antagonists, particularly by mifepristone. However, there are no available crystal structures of AR in an antagonist conformation, and the basis for NCoR/SMRT recruitment by the agonist versus antagonist-liganded AR has been unclear. This study first confirms that there is a ligandindependent interaction between NCoR and the AR NTD. Using site-directed mutagenesis, we then establish that NCoR binding to the mifepristone-liganded AR LBD is mediated by the COOH-terminal N1 CoRNR box. Moreover, we show that the basis for this selectivity is unique charged residues in the NCoR and SMRT N1 CoRNR boxes, which are predicted to be positioned on a helical face adjacent to oppositely charged residues in helix 4 of the AR LBD. Mutagenesis of these residues in helix 4, in conjunction with mutation of K720 in helix 3, further support the conclusion that the N1 CoRNR box is positioned in the coactivator binding site and is being stabilized by charge interactions. Finally, results using a helix 12 -deleted AR indicate that mifepristone induces further conformational changes in the LBD (in addition to helix 12 displacement) that are critical for NCoR binding.
Based on the data in this study, a model for AR-NCoR binding to the agonist versus antagonist-liganded AR is outlined in Fig. 6B . We suggest that NCoR interaction with the agonist-liganded AR is mediated primarily by the AR NH 2 -terminal domain. Significantly, multiple regions of NCoR may mediate this AR NH 2 -terminal domain binding, including a region flanking the N2 CoRNR box identified in this study and a domain in the middle of NCoR that encompassed the third repressor domain (RD3; ref. 42 ).
Moreover, the NH 2 -terminal interaction may be both direct and indirect through TAB2 (40) . SMRT has also been shown to interact with the AR NH 2 -terminal domain, and this interaction may inhibit the agonist-liganded AR by competing for binding of p160 coactivators and impairing the AR NH 2 -/COOH-terminal interaction, as well as by recruiting histone deacetylases. Mifepristone can stabilize this weak binding to the AR NH 2 -terminal domain by mediating a further interaction between the COOHterminal N1 CoRNR box of NCoR and the coactivator binding site in the AR LBD. However, it should be emphasized that whereas mifepristone enhances CoRNR box binding to the AR LBD, this interaction is still quite weak and not readily detectable in the absence of the AR NH 2 -terminal domain interactions.
Significantly, displacement of helix 12 alone is not sufficient to obtain N1 CoRNR box binding, which indicates that further mifepristone-induced conformational changes are required to enhance binding. Our site-directed mutagenesis results indicate that one effect of mifepristone may be to reposition helix 4 in the AR LBD so that charged residues on one face of this helix (D731 and Q738) can bond with oppositely charged residues (arginine and glutamate) that are unique to the N1 CoRNR boxes of NCoR and SMRT. In addition, it is possible that the phenyl-aminodimethyl group in the 11h position makes direct contact with the CoRNR box. This mechanism has been suggested for the PR antagonist asoprisnil, which is structurally related to mifepristone and enhances NCoR binding to the PR (47) . In any case, the important conclusions from these data are that antagonists can alter the structure of the AR coactivator binding site to enhance CoRNR box binding and that this enhancement requires both displacement of helix 12 and additional antagonist-mediated changes in the coactivator binding site.
AR antagonists currently in use (flutamide and bicalutamide) are effective when used as single agents or in combination with castration (androgen deprivation therapy) to suppress AR activity in prostate cancer. However, patients invariably relapse with tumors that have been termed hormone refractory, androgen independent, or castrationresistant prostate cancer. Significantly, AR transcriptional activity is reactivated in these recurrent tumors through unclear mechanisms, but it seem to include increased tumor synthesis of androgens and other adaptations that enhance AR activation in response to low levels of androgens (48) . Unfortunately, AR antagonists are no longer effective at suppressing AR activity in these recurrent tumors. The basis for this loss of activity is unclear but may include alterations in AR or associated proteins that further decrease AR affinity for these antagonists (relative to intracellular testosterone and DHT) or enhance their partial agonist activity. To determine whether mifepristone has activity in these recurrent tumors, we recently completed a small trial of mifepristone in 19 patients with advanced castrationresistant prostate cancer (49). Interpretation of the results was confounded by substantial increases in adrenal androgen levels in response to glucocorticoid receptor blockade by mifepristone, but only 6 patients had evidence of a response based on stable levels of serum PSA and no patients had significant declines in their PSA.
As noted above, whereas mifepristone has provided a proof of principle that ligand-induced conformational changes in the AR LBD can enhance NCoR binding, the interaction between the mifepristone-liganded AR and the N1 CoRNR box is still relatively weak and may limit the efficacy of this drug in advanced castration-resistant prostate cancer. Nonetheless, based on the results of this study, we would predict that additional antagonists can be developed that will further enhance AR recruitment of NCoR and SMRT. Such drugs may be effective in recurrent prostate cancer and may also have novel tissue selective activities based on relative levels of coactivators versus corepressors.
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